Precision Medicine in Pediatric Oncology: Lessons Learned and Next Steps

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2016 Oct 18

PMID 27748023

Citations 38

Authors

Rajen J Mody

John R Prensner

Jessica Everett

D Williams Parsons

Arul M Chinnaiyan

Affiliations

Soon will be listed here.

Abstract

The maturation of genomic technologies has enabled new discoveries in disease pathogenesis as well as new approaches to patient care. In pediatric oncology, patients may now receive individualized genomic analysis to identify molecular aberrations of relevance for diagnosis and/or treatment. In this context, several recent clinical studies have begun to explore the feasibility and utility of genomics-driven precision medicine. Here, we review the major developments in this field, discuss current limitations, and explore aspects of the clinical implementation of precision medicine, which lack consensus. Lastly, we discuss ongoing scientific efforts in this arena, which may yield future clinical applications.

Citing Articles

The childhood cancer data initiative: enabling data sharing to drive research advances and transform pediatric cancer diagnosis and treatment.

Jagu S, Guidry Auvil J, Reaman G Curr Opin Pediatr. 2024; 37(1):42-47.

PMID: 39699099 PMC: 11658014. DOI: 10.1097/MOP.0000000000001422.

The economic costs of precision medicine for clinical translational research among children with high-risk cancer.

Owens C, Tan O, Kuroiwa-Trzmielina J, Shrestha R, OBrien T, Tyrrell V NPJ Precis Oncol. 2024; 8(1):224.

PMID: 39367129 PMC: 11452525. DOI: 10.1038/s41698-024-00711-w.

Translating Precision Health for Pediatrics: A Scoping Review.

Subasri M, Cressman C, Arje D, Schreyer L, Cooper E, Patel K Children (Basel). 2023; 10(5).

PMID: 37238445 PMC: 10217253. DOI: 10.3390/children10050897.

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type.

Subhan M, Parveen F, Shah H, Yalamarty S, Ataide J, Torchilin V Cancers (Basel). 2023; 15(8).

PMID: 37190133 PMC: 10137302. DOI: 10.3390/cancers15082204.

Utilization of Genomic Tumor Profiling in Pediatric Liquid Tumors: A Clinical Series.

Sharma I, Son M, Motamedi S, Hoeft A, Teller C, Hamby T Hematol Rep. 2023; 15(2):256-265.

PMID: 37092520 PMC: 10123750. DOI: 10.3390/hematolrep15020026.

References

McNeil C . NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst. 2015; 107(7). DOI: 10.1093/jnci/djv193. View

Scollon S, Bergstrom K, Kerstein R, Wang T, Hilsenbeck S, Ramamurthy U . Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Med. 2014; 6(9):69. PMC: 4195891. DOI: 10.1186/s13073-014-0069-3. View

Li S, Cheuk A, Shern J, Song Y, Hurd L, Liao H . Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One. 2013; 8(10):e76551. PMC: 3790700. DOI: 10.1371/journal.pone.0076551. View

Sievert A, Lang S, Boucher K, Madsen P, Slaunwhite E, Choudhari N . Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A. 2013; 110(15):5957-62. PMC: 3625308. DOI: 10.1073/pnas.1219232110. View

Chen X, Stewart E, Shelat A, Qu C, Bahrami A, Hatley M . Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013; 24(6):710-24. PMC: 3904731. DOI: 10.1016/j.ccr.2013.11.002. View

Choy E, Butrynski J, Harmon D, Morgan J, George S, Wagner A . Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014; 14:813. PMC: 4230717. DOI: 10.1186/1471-2407-14-813. View

Brenner J, Feng F, Han S, Patel S, Goyal S, Bou-Maroun L . PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012; 72(7):1608-13. PMC: 3319786. DOI: 10.1158/0008-5472.CAN-11-3648. View

Zur Stadt U, Escherich G, Indenbirken D, Alawi M, Adao M, Horstmann M . Rapid Capture Next-Generation Sequencing in Clinical Diagnostics of Kinase Pathway Aberrations in B-Cell Precursor ALL. Pediatr Blood Cancer. 2016; 63(7):1283-6. DOI: 10.1002/pbc.25975. View

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

10.

Perry J, Kiezun A, Tonzi P, Van Allen E, Carter S, Baca S . Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014; 111(51):E5564-73. PMC: 4280630. DOI: 10.1073/pnas.1419260111. View

11.

Farrar J, Schuback H, Ries R, Wai D, Hampton O, Trevino L . Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Res. 2016; 76(8):2197-205. PMC: 4873364. DOI: 10.1158/0008-5472.CAN-15-1015. View

12.

Landrum M, Lee J, Riley G, Jang W, Rubinstein W, Church D . ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2013; 42(Database issue):D980-5. PMC: 3965032. DOI: 10.1093/nar/gkt1113. View

13.

Worst B, van Tilburg C, Balasubramanian G, Fiesel P, Witt R, Freitag A . Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. Eur J Cancer. 2016; 65:91-101. DOI: 10.1016/j.ejca.2016.06.009. View

14.

Murphy D, Reaman G, Jensen C . Pediatric oncology drug shortages: a multifaceted problem. Pediatrics. 2014; 133(3):e728-9. DOI: 10.1542/peds.2013-4018. View

15.

Stein L . The case for cloud computing in genome informatics. Genome Biol. 2010; 11(5):207. PMC: 2898083. DOI: 10.1186/gb-2010-11-5-207. View

16.

Schatz M, Langmead B, Salzberg S . Cloud computing and the DNA data race. Nat Biotechnol. 2010; 28(7):691-3. PMC: 2904649. DOI: 10.1038/nbt0710-691. View

17.

Gajjar A, Stewart C, Ellison D, Kaste S, Kun L, Packer R . Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013; 19(22):6305-12. PMC: 3856244. DOI: 10.1158/1078-0432.CCR-13-1425. View

18.

Bellini A, Bernard V, Leroy Q, Frio T, Pierron G, Combaret V . Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis. Clin Cancer Res. 2015; 21(21):4913-21. DOI: 10.1158/1078-0432.CCR-15-0423. View

19.

Morrissy A, Garzia L, Shih D, Zuyderduyn S, Huang X, Skowron P . Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016; 529(7586):351-7. PMC: 4936195. DOI: 10.1038/nature16478. View

20.

Rehm H, Berg J, Brooks L, Bustamante C, Evans J, Landrum M . ClinGen--the Clinical Genome Resource. N Engl J Med. 2015; 372(23):2235-42. PMC: 4474187. DOI: 10.1056/NEJMsr1406261. View